Compass Group PLC Sponsored ADR (CMPGY)
Compass Minerals International Continues To Trade On The Cheap Even After Soaring
Compass Minerals International remains a ‘buy' as fundamentals strengthen and shares trade at a compelling valuation. Revenue and profitability improved despite volume declines, driven by higher salt prices and operational discipline. Salt segment pricing power offset lower highway salt volumes, while Plant Nutrition benefited from intentional portfolio adjustments.
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity
Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference.
Coinbase Jumps 6% on Compass Point Upgrade Ahead of Senate CLARITY Act Vote; Strategy Climbs 3%, MARA Slips
Coinbase Global (NASDAQ:COIN | COIN Price Prediction) shares are up 6% to $185.
Compass CEO Says 42% of Homes Took a Price Cut
Compass (NYSE:COMP) CEO Robert Reffkin went on CNBC this morning with a striking data point and a buyer-friendly pitch.
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51
CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.
Compass Pathways stock rises as 52-week data show lasting depression relief
Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained efficacy with an infrequent dosing paradigm of two to four times per year.
Here's how the private-listing war between Zillow and Compass could cost home buyers and sellers
Real-estate giants Compass and Zillow are battling over control of home listings. Consumer advocates and industry experts warn that buyers and sellers could pay a price.
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization
Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create interim share price volatility.
Compass Pathways: Still A Buy, But The Exit Just Got Complicated
COMPASS Pathways remains a Buy, but Eli Lilly's acquisition of AtaiBeckley narrows CMPS's long-term strategic options. COMP360's first-mover advantage in treatment-resistant depression is real but fragile, with approval targeted for H1 2027 and launch timelines described as fluid. BPL-003's short-duration sessions may offer superior site economics versus CMPS's 6-hour COMP360 protocol, raising competitive risks.
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.
